PSC
Patient Square Capital Portfolio holdings
AUM
$277M
This Quarter Return
+0.67%
1 Year Return
+6.76%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$269M
AUM Growth
+$269M
(+25%)
Cap. Flow
+$56.5M
Cap. Flow
% of AUM
20.96%
Top 10 Holdings %
Top 10 Hldgs %
99.84%
Holding
11
New
9
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Cullinan Oncology
CGEM
|
$13.8M |
| 2 |
Insmed
INSM
|
$12.5M |
| 3 |
EyePoint Pharmaceuticals
EYPT
|
$10.9M |
| 4 |
Nurix Therapeutics
NRIX
|
$7.32M |
| 5 |
Pharvaris
PHVS
|
$4.49M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$8.15B
| $141M | 52.38% |
12,228,465
| – | – |
|
2
Liquidia Corp
LQDA
$2.38B
| $71.8M | 26.66% |
7,182,532
| – | – |
|
|
3
Cullinan Oncology
CGEM
$445M
| $13.8M | 5.12% |
+824,705
| New | +$13.8M |
|
|
4
Insmed
INSM
$28.8B
| $12.5M | 4.65% |
+171,704
| New | +$12.5M |
|
|
5
EyePoint Pharmaceuticals
EYPT
$797M
| $10.9M | 4.04% |
+1,361,979
| New | +$10.9M |
|
|
6
Nurix Therapeutics
NRIX
$714M
| $7.32M | 2.72% |
+325,789
| New | +$7.32M |
|
|
7
Pharvaris
PHVS
$1.39B
| $4.49M | 1.67% |
+242,341
| New | +$4.49M |
|
8
Intellia Therapeutics
NTLA
$1.22B
| $2.64M | 0.98% |
+128,569
| New | +$2.64M |
|
9
Enliven Therapeutics
ELVN
$1.2B
| $2.31M | 0.86% |
+90,572
| New | +$2.31M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $2.05M | 0.76% |
+235,498
| New | +$2.05M |
|
11
Astria Therapeutics
ATXS
$349M
| $434K | 0.16% |
+39,422
| New | +$434K |
|